Fibrosarcoma Market

Fibrosarcoma Market Analysis by Treatment Type (Chemotherapy, Radiation Therapy, Surgery), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), by End-User, by Region - Global Forecast 2022-2032

Analysis of Fibrosarcoma market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Global Fibrosarcoma Market Outlook

The global fibrosarcoma market is evaluated at USD 349.9 Million in 2022 and is forecast to outshine USD 612.7 Million by 2032, mounting at a CAGR of 5.8% from 2022 to 2032.

Report Attributes


Base Year Value (2021A)

USD 332.5 Million

Estimated Year Value (2022E)

USD 349.9 Million

Projected Year Value (2032F)

USD 612.7 Million

Global Growth Rate (2022-2032)


North America Market Share in 2021


North America Growth Rate (2022-2032)


Collective Value Share (China, USA, Germany) 2022: Top 3 Countries


Top 5 Companies Market Share in 2021


Key Companies Profiled

  • Cadila Pharmaceuticals Limited
  • Celon Laboratories Limited
  • Bristol-Myers Squibb Company
  • Dr. Reddy's Laboratories Limited
  • Sun Pharmaceutical Industries Limited
  • Novartis AG
  • Baxter International Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Johnson & Johnson
  • .Other Key Players

Fibrosarcoma is a rare type cancer that impacts the soft connective tissues in the body. Such type of connective tissues hold the organs, muscles, and bones, in their proper place. Fibrosarcoma tumors can appear in any part of the body but are most frequently found in the head, abdomen, legs, neck and pelvis. This type of cancer has its origins based in cells called fibrocytes that make up such soft connective tissue.

Further, global fibrosarcoma market holds nearly 25.7% market share in global sarcoma therapeutics market which is likely to grow at a CAGR of 7.9% during the forecast years.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

2017-2021 Global Fibrosarcoma Market Outlook in Comparison to 2022-2032 Growth Forecast

All along 2017-2021, the historic year's global fibrosarcoma market observed slow growth with 3.9%. Consumers with the mounting needs and amplified spending by the governments in the innovative technologies advancement have prospered the fibrosarcoma market.

Owing to following aspects, the demand of fibrosarcoma can be assessed during the forecast period by split the assessment timeline into three sections

1. Short-run: recovery growth is slow over the short –term of 3 years.

2. Medium-run: price and sales normalization are likely to rise throughout this time frame.

3. Long-run: fibrosarcoma sales and pricing are ostentatious by inflation rates, technologies and economic cycles.

Global fibrosarcoma market has reached at the valuation of USD 332.5 million by the end of 2021 with the growth of 3.9% CAGR. It has generated and absolute dollar opportunity of around USD 58 million in last half-decade.

The growing population with fibrosarcoma cancer likely to drive the demand for the treatment in coming years which will boost the growth of the market. However, market is likely to grow at the 5.8% CAGR and offer and touch the valuation of USD 612.7 million by the end of 2032.

The fibrosarcoma demand is expected to increase at a steady rate during the forecast period at a CAGR of around 5.8%. Creating an optimistic approach for the market participants, with a purpose on the addition of health safety features in the fibrosarcoma.

Fact.MR projects the fibrosarcoma market is expected to witness the growth of 5.8% CAGR during 2022 & 2032 in comparison to a CAGR of 3.9% with which it grew from 2017 and 2021.

Few New Treatments on the anvil in the global Fibrosarcoma Market

The rarity of bone sarcomas such as fibrosarcoma makes it difficult to perform outcome studies on enough cases. Collaborations between centers and large referral centers provide the best opportunity to amass a sufficient number of patients,

However, the heterogeneity of observers, treating physicians, and patients brings its own set of challenges. Diagnostic criterion difference could result in the complete inclusion or exclusion of patients from studies. Medical oncologists can also differ in drug regimen preferences, particularly in the case of their older patients who may have lesser tolerance to side-effects.

Further, an increased willingness and tolerance to treat side effects may lead to some healthcare personnel continuing chemotherapy longer than their peers. Differences in surgical skills and technique also come into play with respect to patient outcomes.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Additional Research needed to Treat Fibrosarcoma Effectively

Fibrosarcoma is a rare bone malignancy. Although it is similar in some aspects to other sarcomas, fibrosarcoma is a distinct clinical entity that has many unique characteristics. Fibrosarcoma outcome improvement has been lagging compared to that of other bone sarcomas.

It is impossible to perform large-scale randomized trials as the fibrosarcoma cases are few and far between. Even larger cancer centers report few, if any, cases of bone primary fibrosarcoma annually. Surgery is currently the preferred form of treatment but transitional research advancements could hold the key to novel targets for systemic treatment.

The notable trend to treat these rare cases of fibrosarcoma at cancer centers with medical professionals specializing in its treatment offers the best possible hope to maximize care and gather crucial data to treat future generations.

Increasing Geriatric Population More Prone to Fibrosarcoma

Fibrosarcoma strikes people who lie in the age bracket of 25-79. The peak age where this disease occurs is in the age bracket of 55-69 years. In most of the cases, both men and women are equally prone to fibrosarcomas, although this kind of disease is rare in children.

In addition, as the fertility rates have lowered in most regions of the world and since life expectancy has increased, the geriatric population of the world continues to grow rapidly. In the year 2012, when the world population touched a figure of 7 billion, 562 million people or 8 percent of the population were aged 65 and above. In the year 2015, this figure has reached 8.5 percent of the population.

With the geriatric population more at risk due to this disease, the regions where there the geriatric population is growing are likely to have more cases of fibrosarcomas.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Country-wise Insights

Why the United States has Enormous Market for Fibrosarcoma?

Cancer has a massive impact on American and global society as a whole. According to statistics from National Cancer Institute, more than 1.8 million cases of cancer were diagnosed in the U.S in 2020 and approx. half a million perished. Cancer mortality is usually higher in men than in women with the maximum cases reported in African American men.

Further, roughly 2/5th of all American men and women will be diagnosed with cancer at some point in their lives, making national cancer expenditure a considerable healthcare burden. Although the overall cancer death rate has certainly declined since the early 90’s, the rates for some cancer have remained stable or even increased.

In the case of soft tissue sarcoma, the Institute estimates 5-year survival rate to be in the range of 50%. The statistics take into account Kaposi sarcoma – a form of sarcoma that has a relatively poorer outlook than other types. The 10-year survival rates are slightly lower indicating that the bulk of patients who survive five years are probably cured. This reinforces the need to detect fibrosarcoma as soon as possible so that treatment can be administered and is effective.

However, the United States fibrosarcoma market is projected to grow at a CAGR of 6.8% and generate and absolute dollar opportunity of nearly USD 102 million by the end of 2032.

Why is Mexico Fibrosarcoma Market making Enormous Market for Fibrosarcoma?

Cancer is the second-largest killer in the Latin American countries and its burden is likely to grow more in the years to come. In the major countries of Latin America, cancer is the cause of 19 percent of all the deaths on average.

Due to the growing population and growth in the proportion of geriatric population in Latin America, the mortality in the region is set to rise between 2012 and 2035. The number of cases of cancer are projected to rise by 91 percent during this time span, and the cancer related deaths are related to rise by a whopping 106 percent. Due to this, the economic costs of cancer for the region are also set to increase significantly.

Mexico fibrosarcoma market is the leading region in Latin America which is acquiring significant market share. It is expected to grow at a CAGR of 5.8% and offer significant absolute dollar opportunities over the assessment period.

Fibrosarcoma market forecast by Fact.MR

Category-wise Insights

Which Treatment Type Having Highest In Demand in the Fibrosarcoma Market?

Fibrosarcoma is a type of malignant mesenchymal tumor primarily from fibrous connective tissue and known for the presence of undifferentiated anaplastic spindle cells or immature proliferating fibroblasts in a specific pattern. Fibrosarcoma is most commonly observed in males between the age of thirty and forty years.

Chemotherapy is the foremost treatment which is widely adopted by the patients and doctors to treat the fibrosarcoma. Owing to this chemotherapy treatment type has acquired more than 2/5th market share in global market. This likely to continue its dominance in global market during the forecast years.

Which End-User segment is Poised to Show Lucrative Growth in Fibrosarcoma Market?

The majority of the patients with fibrosarcoma primarily visit the hospitals to get tests done as well as treatment as well. The chemotherapy treatment is primarily done in hospitals merely owing to which the hospitals end-user type has acquired largest market share in global market. However, the hospitals end-user type hold nearly 1/3rd of the market share in the fibrosarcoma market. It is expected to continue its dominance during the forecast years as well.

Competitive Landscape: Top Companies in Fibrosarcoma Market

To recover penetration across well-paid markets, the above-mentioned companies use a combination of organic and inorganic strategies. Alliances and agreements with leading fibrosarcoma suppliers, acquisitions, product launches, merger, and the geographical expansion all part of these strategies.

Fact.MR has provided detailed information about price points of top manufacturers of fibrosarcoma market positioned across regions, sales growth, production capacity, and speculative technological expansion in the recently published report.

For instance:

  1. In July 2022, Cadila Pharmaceuticals Limited has expanded its oncology offering portfolio with the launch of Bevasizumab biosimilar cancer drug Bevaro™
  2. In June 2021, Bristol-Myers Squibb Company has collaborated strategically with Eisai Co., Ltd. co-development and co-commercialization of MORAb-202 drug

Global Fibrosarcoma Market by Category

  • By Treatment Type, Global Fibrosarcoma Market is segmented as:

    • Chemotherapy
    • Radiation Therapy
    • Surgery
    • Other Therapy
  • By End-User, Global Fibrosarcoma Market is segmented as:

    • Hospitals
    • Clinics
    • Specialized Cancer Treatment Centers
    • Other End Users
  • By Distribution Channel, Global Fibrosarcoma Market is segmented as:

    • Hospital Pharmacy
    • Retail Pharmacy
    • E-Commerce
    • Other Distribution Formats
  • By Region, Global Fibrosarcoma Market is segmented as:

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

- FAQs -

What is the global Fibrosarcoma Market scenario?

The global value of fibrosarcoma market is estimated to be worth over USD 349.9 Million in 2022.

How far is the global demand expected to reach over the forecasted period?

The demand is anticipated to surpass USD 612.7 Million by 2032 end.

What was the last 5-year CAGR for the demand in the Fibrosarcoma Market?

During 2017-2021, global fibrosarcoma market grew at 3.9% CAGR.

Who are the prominent players in the global Fibrosarcoma Market?

Some of the prominent players in fibrosarcoma market are Cadila Pharmaceuticals Limited, Celon Laboratories Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Limited, Sun Pharmaceutical Industries Limited Etc.

Which is the most leading region in the Fibrosarcoma Market?

North America tops the global fibrosarcoma market accounting for more than 1/3rd of global market share in 2022.

Which treatment type segment contributes maximum share in Fibrosarcoma Sales?

Chemotherapy segment contributes by holding 2/5th of market share in global sales of fibrosarcoma.

Fibrosarcoma Market

Schedule a Call